Recovery and assessment timescales in primary immunodeficiency extend from weeks to months. Initial post-infusion inflammatory responses subside within 1–2 weeks. Meaningful immune reconstitution — increased T-cell counts, restored T-cell proliferation — usually requires 4–12 weeks to manifest, reflecting lymphoid tissue regeneration timescales. T-cell subset enumeration, T-cell proliferation assays, and immunoglobulin levels are typically assessed at baseline, 4 weeks, 8 weeks, 12 weeks, 6 months, and 12 months post-infusion. Vaccine responses are re-assessed at 3–6 months post-infusion to measure functional antibody recovery. Infection monitoring continues throughout recovery; prophylactic antimicrobial therapy is typically maintained during early immune reconstitution. Patients should expect gradual immune improvement over months rather than acute recovery.
Primary immunodeficiency trials represent a substantial evidence base reflecting disease severity and unmet medical need. Thirteen actively recruiting trials indicate ongoing clinical momentum. Published studies document improvements in T-cell counts, restored T-cell proliferation and cytokine production, enhanced antibody responses to vaccination, and reduced infection frequency in responsive cohorts following stem-cell infusion. Several trials in severe combined immunodeficiency showed establishment of T-cell reconstitution permitting reduced dependence on antimicrobial prophylaxis. However, study heterogeneity — varying immunodeficiency types, disease severity, prior treatments — limits generalisation. Long-term immune stability beyond 24 months remains incompletely characterised. Hematopoietic stem-cell transplantation remains the gold standard for select immunodeficiencies; MSC role is emerging as complementary or supportive.
Am I a candidate? → · Primary Immunodeficiency: full overview → · Primary Immunodeficiency cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicina regenerativa certificada GMP en el corazón de la UE — desde 3.000–8.000 €, una fracción de los precios de EE. UU. o Alemania. Protocolos personalizados para pacientes de más de 50 países.
Evaluación médica gratuita